NDAINTRAVENOUS, SUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
22
Data completeness
5/8 — Partial
Priority Review
VELCADE (bortezomib) by Takeda is proteasome inhibitors [moa]. Approved for proteasome inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELCADE (bortezomib) is a proteasome inhibitor small molecule administered intravenously or subcutaneously that blocks cancer cell protein degradation pathways. It is indicated for multiple myeloma, mantle cell lymphoma, and other hematologic malignancies. The drug works by inhibiting the 26S proteasome, leading to accumulation of pro-apoptotic proteins and cancer cell death.
$0.002BPart D
LOE ApproachingProduct is in LOE approaching phase with modest Part D claims (399 in 2023), indicating mature market with declining volume and likely smaller dedicated commercial team.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (22)
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Started Oct 2026
20 enrolled
Multiple Myeloma
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
Started Aug 2026
120 enrolled
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started Jul 2026
500 enrolled
Multiple Myeloma
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Started Jun 2026
720 enrolled
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Started Mar 2026
60 enrolled
Amyloidosis
Worked on VELCADE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.